Weekly paclitaxel may provide prolonged complete remission in patients with secondary breast angiosarcoma, with recurrences responding to treatment resumption.
No takes yet. Share an insight, caveat, or question.
May support paclitaxel in rare secondary breast angiosarcoma; leaves open need for prospective trials before practice change.
Gambini et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: